Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
100.00    -3.20 (-3.10%)
Bid:
100.00
Ask:
102.00
Spread: 2.00 (2.00%)
Market Cap: £163.94m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

AGM & Interim Management Statement

14 May 2009 07:00

RNS Number : 1992S
Yule Catto & Co PLC
14 May 2009
 

14 May 2009

Yule Catto & Co plc 

AGM and Interim Management Statement

At today's Annual General Meeting of Yule Catto & Co plc, an international producer of speciality chemicals, Peter Wood, Chairman, will make the following statement, which comprises Yule Catto's Interim Management Statement for the period from 1 January 2009 to date.

Trading update

2009 has started satisfactorily given the very difficult macro economic environment. The Group has benefited from the weakness of sterling, and overall the Group has traded in line with management expectations.

In Polymer Chemicals, the substantial volume declines seen in the fourth quarter of 2008 persisted into 2009 although March was slightly better than the first two months of the year.

Pharma Chemicals had a good first quarter compared to what was a relatively weak start to 2008. Profits were in line with our expectations for a stronger full year performance in 2009. 

William Blythe, the remaining Impact Chemicals business was ahead of last year as expected, and benefited from the restructuring implemented at the end of the first quarter of 2008.

The Group announced a number of cost reduction initiatives with its full year 2008 results which are on track.

Following the successful refinancing at the year end with a new revolving finance facility and Malaysian term loan, the Group is making good progress on its debt reduction target. 

Looking forward we continue to expect the Pharma business to deliver higher profits than 2008, assisted by the favourable €/$ exchange rate and increased capacities for a number of products. Similarly William Blythe should continue to trade satisfactorily following its restructuring. Volume declines in Polymers moderated at the end of the first quarter but the outlook for the balance of the year remains uncertain. A large proportion of the Polymer Division's sales are in Europe and Asia and hence we are currently benefiting from the weakness of sterling. Given the uncertainty in our end markets, it is difficult to give any firm guidance on the outturn for Polymers for the full year and hence the Group as a whole.

Board Changes

Further to the retirement of Anthony Richmond-Watson, two other non executive directors will be retiring at this Annual General Meeting:- Dato' Seri Lee Oi Hian, who joined the Board in 1981 and is Chief Executive of Kuala Lumpur Kepong Bhd which has been a major shareholder in the Company since 1976; and Richard Hunting, an independent non executive director, who joined the Board in 2000 and has been Chairman of the Nomination Committee since 2001 and a member of the Audit Committee for nine years. I would like to thank all of them for their valuable contribution to the Group.

We are delighted to welcome Graham Menzies who joined the Board on 1 March this year. Graham's biographical details are in the circular that accompanied the 2008 Annual Report and he has been appointed as the Senior Independent Director after a distinguished career as a public company chief executive.

These changes complete the realignment of our Board structure and we believe that the Board, as currently constituted, is appropriate and balanced to serve the future needs of the Group.

ENQUIRIES:

YULE CATTO & Co plc

Tel: 01279 442791

Adrian Whitfield, Chief Executive 

David Blackwood, Finance Director 

 

HOGARTH PARTNERSHIP

Tel: 020 7357 9477

John Olsen

Andrew Jaques

Ian Payne

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSAJMATMMBBBBL
Date   Source Headline
1st Jun 20262:42 pmRNSHolding(s) in Company
29th May 20263:57 pmRNSTotal Voting Rights
22nd May 20265:21 pmRNSNotice of AGM
8th May 20264:33 pmRNSAdmission to Trading
7th May 20261:51 pmRNSApplication for Admission to Trading
5th May 20264:25 pmRNSHolding(s) in Company
30th Apr 20264:40 pmRNSAnnual Financial Report
30th Apr 20263:17 pmRNSDirector/PDMR Shareholding
30th Apr 202611:25 amRNSDirector/PDMR Shareholding
30th Apr 20267:01 amRNSChange of Chief Financial Officer
30th Apr 20267:00 amRNSFinal Results
19th Mar 20267:00 amRNSTrading and refinancing update
11th Feb 20261:46 pmRNSStatement re potential refinancing
29th Jan 20267:00 amRNSTrading Statement - Winter 2026
27th Jan 20264:51 pmRNSHolding(s) in Company
26th Jan 20264:23 pmRNSHolding(s) in Company
18th Dec 20257:00 amRNSReceivables purchasing arrangement
12th Dec 20259:30 amRNSDirectorate change
12th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20251:28 pmRNSHolding(s) in Company
23rd Oct 20257:00 amRNSTrading statement - Autumn 2025
14th Oct 20257:00 amRNSAppointment of joint corporate broker
4th Sep 20255:17 pmRNSHolding(s) in Company
11th Aug 20258:00 amRNSDirector/PDMR Shareholding
6th Aug 20259:45 amRNSDirector/PDMR Shareholding
5th Aug 202511:57 amRNSDirector/PDMR Shareholding
5th Aug 202511:00 amRNSDirectorate Change
5th Aug 20257:00 amRNSInterim results
4th Jul 20257:01 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSCovenant update
30th Jun 20257:00 amRNSDirectorate Changes
27th Jun 20254:21 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDivestment of William Blythe completed
6th May 20257:00 amRNSDivestment of William Blythe
1st May 20254:18 pmRNSResults of AGM
1st May 20257:00 amRNSTrading Statement - Spring 2025
15th Apr 20253:00 pmRNSHolding(s) in Company
28th Mar 20257:30 amRNSDirector/PDMR Shareholding
27th Mar 20257:30 amRNSDirector/PDMR Shareholding
25th Mar 20254:23 pmRNSAnnual Report and Notice of AGM
25th Mar 202511:43 amRNSDirector/PDMR Shareholding
25th Mar 202511:41 amRNSDirector/PDMR Shareholding
24th Mar 20257:30 amRNSHolding(s) in Company
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
11th Mar 20257:00 amRNSFinal Results
6th Mar 20258:32 amRNSDirector Declaration
13th Feb 20257:00 amRNSHolding(s) in Company
28th Jan 202510:30 amRNSDirector/PDMR Shareholding
28th Jan 20257:00 amRNSWinter trading statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.